|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
47,500,000 |
Market
Cap: |
2.01(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.65 - $65 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Amphastar Pharmaceuticals is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing and selling generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient (API) products. Co.'s reportable segments are: finished pharmaceutical products, which manufactures, markets and distributes Primatene Mist®, glucagon, enoxaparin, naloxone, phytonadione, lidocaine, epinephrine, various critical and non-critical care drugs; and API, which manufactures and distributes recombinant human insulin API and porcine insulin API for external customers and internal product development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,000 |
384,322 |
579,546 |
794,601 |
Total Sell Value |
$42,551 |
$21,525,712 |
$32,066,990 |
$40,646,784 |
Total People Sold |
1 |
4 |
8 |
10 |
Total Sell Transactions |
2 |
10 |
25 |
62 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2016-09-21 |
4 |
AS |
$20.70 |
$1,140,334 |
D/D |
(55,081) |
1,088,335 |
|
- |
|
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2016-09-21 |
4 |
OE |
$16.75 |
$922,772 |
D/D |
55,081 |
1,143,416 |
|
- |
|
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2016-09-20 |
4 |
AS |
$20.74 |
$3,825,732 |
I/I |
(181,768) |
752,321 |
|
- |
|
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2016-09-20 |
4 |
OE |
$16.75 |
$3,045,159 |
I/I |
181,768 |
934,089 |
|
- |
|
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2016-09-20 |
4 |
AS |
$20.73 |
$4,376,738 |
D/D |
(207,350) |
1,088,335 |
|
- |
|
Luo Mary Z. |
COO Chief Scientist & Chairman |
|
2016-09-20 |
4 |
OE |
$16.75 |
$3,473,735 |
D/D |
207,350 |
1,295,685 |
|
- |
|
Petersen Floyd F. |
Director |
|
2016-09-08 |
4 |
S |
$19.05 |
$57,150 |
D/D |
(3,000) |
60,317 |
|
- |
|
Lee Howard |
Director |
|
2016-09-01 |
4 |
S |
$18.78 |
$194,917 |
D/D |
(10,381) |
114,527 |
|
- |
|
Lee Howard |
Director |
|
2016-09-01 |
4 |
OE |
$15.23 |
$158,103 |
D/D |
10,381 |
125 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-08-22 |
4 |
AS |
$19.95 |
$199,500 |
D/D |
(10,000) |
202,961 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-08-22 |
4 |
OE |
$10.46 |
$104,600 |
D/D |
10,000 |
212,961 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2016-08-19 |
4 |
AS |
$19.28 |
$463,607 |
D/D |
(24,046) |
28,985 |
|
- |
|
Gerst Diane G. |
EVP, QA & Regulatory Affairs |
|
2016-08-19 |
4 |
OE |
$10.93 |
$295,975 |
D/D |
24,046 |
53,031 |
|
- |
|
Prins Richard K |
Director |
|
2016-08-18 |
4 |
S |
$19.62 |
$60,539 |
D/D |
(3,086) |
26,000 |
|
- |
|
Shandell Jason B. |
President and General Counsel |
|
2016-08-17 |
4 |
AS |
$18.86 |
$112,909 |
D/D |
(5,987) |
202,961 |
|
- |
|
Shohet Stephen B. |
Director |
|
2016-08-16 |
4 |
S |
$18.35 |
$195,784 |
D/D |
(10,670) |
18,272 |
|
- |
|
Shohet Stephen B. |
Director |
|
2016-08-16 |
4 |
OE |
$14.23 |
$151,834 |
D/D |
10,670 |
28,942 |
|
- |
|
Zasloff Michael A |
Director |
|
2016-08-15 |
4 |
S |
$18.22 |
$316,972 |
D/D |
(17,400) |
32,411 |
|
- |
|
Zasloff Michael A |
Director |
|
2016-08-15 |
4 |
OE |
$14.23 |
$247,602 |
D/D |
17,400 |
49,811 |
|
- |
|
Shohet Stephen B. |
Director |
|
2016-08-15 |
4 |
S |
$18.26 |
$418,485 |
D/D |
(22,917) |
18,272 |
|
- |
|
Shohet Stephen B. |
Director |
|
2016-08-15 |
4 |
OE |
$14.23 |
$326,109 |
D/D |
22,917 |
41,189 |
|
- |
|
Zasloff Michael A |
Director |
|
2016-08-12 |
4 |
S |
$18.12 |
$561,134 |
D/D |
(30,975) |
32,411 |
|
- |
|
Zasloff Michael A |
Director |
|
2016-08-12 |
4 |
OE |
$14.23 |
$451,155 |
D/D |
30,975 |
63,386 |
|
- |
|
Shohet Stephen B. |
Director |
|
2016-08-12 |
4 |
S |
$18.12 |
$268,012 |
D/D |
(14,788) |
18,272 |
|
- |
|
Shohet Stephen B. |
Director |
|
2016-08-12 |
4 |
OE |
$14.23 |
$220,814 |
D/D |
14,788 |
33,060 |
|
- |
|
956 Records found
|
|
Page 30 of 39 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|